Literature DB >> 2747836

Comparative study of sulpiride and haloperidol on dopamine turnover in the rat brain.

Y Imazu1, K Kobayashi, T Shohmori.   

Abstract

The effects of the neuroleptics, sulpiride and haloperidol, on dopamine (DA) turnover were compared following the acute and chronic administration of these drugs alone or in combination with levodopa or apomorphine. In the acute treatment, the increase in DA metabolites in the striatum and nucleus accumbens was more marked in the haloperidol-treated rats than in the sulpiride-treated rats. Following the additional administration of levodopa, however, the potency of the neuroleptics in elevating DA metabolites was reversed. A low dose of apomorphine induced a marked reduction in the striatal DA metabolite levels by approximately 50%. When rats were pretreated with the neuroleptics, haloperidol was more effective in preventing an apomorphine-induced reduction in DA metabolites. On repeated administration of the neuroleptics, a tolerance occurred in the striatum and nucleus accumbens, but not in the prefrontal cortex. This differential development of tolerance was observed in the different brain regions and with the different drugs administered. These results suggest that the pharmacological mechanism of sulpiride on DA turnover differs from that of haloperidol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747836     DOI: 10.1007/bf00964861

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  [Therapeutic method derived from hiberno-therapy in excitation and agitation states].

Authors:  J DELAY; P DENIKER; J M HARL
Journal:  Ann Med Psychol (Paris)       Date:  1952-07       Impact factor: 0.380

Review 2.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

Review 3.  Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

Authors:  P Muller; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

4.  Biphasic actions of L-DOPA on the release of endogenous noradrenaline and dopamine from rat hypothalamic slices.

Authors:  Y Goshima; T Kubo; Y Misu
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

5.  Mesocortical dopamine neurons. Lack of autoreceptors modulating dopamine synthesis.

Authors:  M J Bannon; R L Michaud; R H Roth
Journal:  Mol Pharmacol       Date:  1981-03       Impact factor: 4.436

6.  Determination of p-hydroxyphenylacetic acid in cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection.

Authors:  K Kobayashi; Y Koide; T Shohmori
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

Review 7.  Radioreceptor labeling of pre- and postsynaptic dopamine receptors.

Authors:  M Titeler; P Seeman
Journal:  Adv Biochem Psychopharmacol       Date:  1980

8.  Rapid concurrent automated fluorimetric assay of noradrenaline, dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 3-methoxytyramine in milligram amounts of nervous tissue after isolation on Sephadex G10.

Authors:  B H Westerink; J Korf
Journal:  J Neurochem       Date:  1977-10       Impact factor: 5.372

9.  Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.

Authors:  N Montanaro; R Dall'Olio; O Gandolfi; A Vaccheri
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

10.  Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey).

Authors:  N G Bacopoulos; D E Redmond; J Baulu; R H Roth
Journal:  J Pharmacol Exp Ther       Date:  1980-01       Impact factor: 4.030

View more
  1 in total

1.  Alcohol-induced behavioral changes in zebrafish: The role of dopamine D2-like receptors.

Authors:  Steven Tran; Amanda Facciol; Robert Gerlai
Journal:  Psychopharmacology (Berl)       Date:  2016-03-09       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.